1.TRAF6/ERK/p38 pathway is involved in interleukin-17-mediated autophagy to promote osteoclast precursor cell differentiation.
Zhongxiu WANG ; Jiahui ZHONG ; Jingyi TAN ; Yeqi SHEN ; Lili CHEN
Journal of Zhejiang University. Medical sciences 2021;50(2):162-170
To investigate the effects of interleukin (IL)-17-mediated autophagy on the TNF receptor associated factor (TRAF6)/extracellular signal-regulated kinase (ERK)/p38 pathway and osteoclast differentiation. Mouse bone marrow-derived macrophages (BMM) were cultured with a medium containing 30 ng/mL macrophage colony stimulating factor and 50 ng/mL receptor activator of nuclear factor-kappa B ligard (RANKL), and IL-17 (0.01, 0.1, 1.0, 10 ng/mL) was added for intervention (IL-17 group). Tartrate-resistant acid phosphatase (TRAP) staining was used to observe TRAP positive multinucleated cells; phalloidin fluorescent staining was used to detect actin ring circumference; toluidine blue staining was used to analyze bone resorption lacuna formation. To further examine the mechanism of the effect of IL-17-mediated autophagy on the differentiation of osteoclasts, the control group used RANKL medium to culture mouse macrophage RAW264.7 cells, while the IL-17 group was treated with IL-17 (0.01, 0.1, 1.0, /mL). Western blot was used to detect the expression of autophagy-related proteins Beclin-1, microtubule-associated protein 1 light chain 3 (LC3) and osteoclast-related proteins c-fos and nuclear factor of activated T cell 1 (NFATc1) after treatment with different concentrations of IL-17. The expression of LC3, NFATc1, TRAF6/ERK/p38 signaling pathway related proteins were detected in IL-17 and autophagy inhibitor 3-MA group. The number of TRAP positive multinucleated cells, the circumference of the actin ring and the area of bone resorption lacuna in IL-17 group treated with IL-17 (0.01, 0.1, were significantly higher than those in the control group. In IL-17 treated RAW264.7 cells, the expression of c-fos, NFATc1, Beclin-1, LC3, TRAF6, p-ERK, and p-p38 was all significantly up-regulated (all 0.05). After treatment with the autophagy inhibitor 3-MA, the expression levels of LC3, NFATc1, TRAF6, p-ERK, and p-p38 all decreased significantly (all 0.05). IL-17 can promote the expression of autophagy proteins and enhance the differentiation ability of osteoclast precursor cells, and the TRAF6/ERK/p38 signaling pathway may be involved in this process.
Animals
;
Autophagy
;
Bone Resorption
;
Cell Differentiation
;
Extracellular Signal-Regulated MAP Kinases
;
Interleukin-17
;
Mice
;
NFATC Transcription Factors/metabolism*
;
Osteoclasts/metabolism*
;
RANK Ligand/metabolism*
;
TNF Receptor-Associated Factor 6
2.Effects of down-regulated TRAF6 gene expression on the proliferation and apoptosis in multiple myeloma cells.
Hong-ming HUANG ; Xing-feng WANG ; Xin-xin LIU ; Rui-rong XU ; Wei SHI ; Run-sheng DING ; Sheng-hua JIANG
Chinese Journal of Hematology 2013;34(11):941-945
OBJECTIVETo investigate the down-regulated TRAF6 gene expression and its effects on proliferation and apoptosis in multiple myeloma (MM) cells.
METHODSDetection of TRAF6 expression were conducted by RT-PCR and Western blot in MM cell lines of KM3, U266, RPMI8226 and primary cells from patients. RPMI8226 cell lines were transfected with siRNA of TRAF6. The efficiency of transfection was identified by using of fluorescence microscope, RT-PCR, and Western blot. The levels of proliferation were analyzed by CCK-8 method under the different concentrations of siRNA. Apoptosis rate were detected with Hoechst33258/PI double staining by flow cytometry. Apoptosis related proteins Bcl-2, BAX, and NF-κB signal pathway were observed before and after siRNA transfection by Western blot.
RESULTSThe levels of TRAF6 mRNA and protein in MM cell lines, especially in primary myeloma cells, were significantly higher than those in controls. After transfected with 50 nmol/L siRNA in RPMI8226 cells, the relative level of TRAF6 mRNA (0.49±0.24) was significantly lower than that in non-transfected group (1.87±0.23) and idling group (1.74±0.35). The proliferation rate of siRNA transfected cells decreased with dose dependence (P<0.01). The apoptosis rates increased from 11.20% (before transfection) to 51.82% (after transfection), accompanied by down-regulated Bcl-2 protein, NF-κB signal pathway (p-p65 and p52), and up-regulated BAX protein.
CONCLUSIONTRAF6 expression was high in myeloma cells. TRAF6 siRNA could inhibit proliferation of myeloma cells and induce apoptosis mediated by NF-κB classical and alternative pathway in myeloma cells.
Case-Control Studies ; Cell Proliferation ; Down-Regulation ; Female ; Gene Expression ; Humans ; Male ; Multiple Myeloma ; metabolism ; pathology ; TNF Receptor-Associated Factor 6 ; genetics ; metabolism ; Tumor Cells, Cultured
3.Competition between TRAF2 and TRAF6 regulates NF-kappaB activation in human B lymphocytes.
Wen ZHANG ; Xuan ZHANG ; Xiao-Li WU ; Liu-Sheng HE ; Xiao-Feng ZENG ; Amrie C CRAMMER ; Peter E LIPSKY
Chinese Medical Sciences Journal 2010;25(1):1-12
OBJECTIVETo investigate the role of TNF receptor-associated factor 2 (TRAF-2) and TRAF6 in CD40-induced nuclear factor-kappaB (NF-kappaB) signaling pathway and whether CD40 signaling requires TRAF2.
METHODSHuman B cell lines were transfected with plasmids expressing wild type TRAF2 or dominant negative TRAF2, TRAF2-shRNA, or TRAF6-shRNA. The activation of NF-kappaB was detected by Western blot, kinase assay, transfactor enzyme-linked immunosorbent assay (ELISA), and fluorescence resonance energy transfer (FRET). Analysis of the role of TRAF-2 and TRAF-6 in CD40-mediated NF-kappaB activity was examined following stimulation with recombinant CD154.
RESULTSTRAF2 induced activity of IkappaB-kinases (IKKalpha, IKKi/epsilon), phosphorylation of IkappaBalpha, as well as nuclear translocation and phosphorylation of p65/RelA. In contrast, TRAF6 strongly induced NF-kappaB activation and nuclear translocation of p65 as well as p50 and c-Rel. Engagement of CD154-induced nuclear translocation of p65 was inhibited by a TRAF6-shRNA, but conversely was enhanced by a TRAF2-shRNA. Examination of direct interactions between CD40 and TRAFs by FRET documented that both TRAF2 and TRAF6 directly interacted with CD40. However, the two TRAFs competed for CD40 binding.
CONCLUSIONSThese results indicate that TRAF2 can signal in human B cells, but it is not essential for CD40-mediated NF-kappaB activation. Moreover, TRAF2 can compete with TRAF6 for CD40 binding, and thereby limit the capacity of CD40 engagement to induce NF-kappaB activation.
Animals ; B-Lymphocytes ; cytology ; physiology ; CD40 Antigens ; metabolism ; Cell Line ; Extracellular Signal-Regulated MAP Kinases ; metabolism ; Fluorescence Resonance Energy Transfer ; Humans ; I-kappa B Kinase ; metabolism ; NF-kappa B ; genetics ; metabolism ; Proto-Oncogene Proteins c-fos ; metabolism ; Signal Transduction ; physiology ; TNF Receptor-Associated Factor 2 ; genetics ; metabolism ; TNF Receptor-Associated Factor 6 ; genetics ; metabolism ; Transcription Factor RelA ; metabolism ; p38 Mitogen-Activated Protein Kinases ; metabolism
4.Effect of yiqi huoxue recipe containing drug-serum on the Toll-Iike receptor-4 and its downstream signaling components MyD88 as well as the tumor necrosis factor receptor related factor-6 in human vein endothelial cells.
Hua JIANG ; Yan ZHANG ; Chen WANG
Chinese Journal of Integrated Traditional and Western Medicine 2010;30(5):519-522
OBJECTIVETo investigate the influence of Yiqi Huoxue Recipe (YHR) containing drug-serum on the expression of Toll-like receptor-4 (TLR4) and its downstream signaling components MyD88, as well as the tumor necrosis factor receptor related factor-6 (TRAF-6) in human vein endothelial cells (HUVECs) induced by lipopolysaccharide (LPS), and to study its possible anti-atherosclerotic mechanism from the gene and protein levels.
METHODSTwenty New Zealand male rabbits were equally divided into four groups in random: the normal control group and the three YHR groups, 5 in each group. They were gastric perfused daily with normal saline and YHR in low, moderate and high concentration respectively. Blood drawn from rabbits' heart 2 h after ending perfusion on the 7th day, and the serum separated (that is the drug-serum) was taken for testing. HUVECs were cultured in vitro and equally divided into six groups in random: the normal control group, the model group, the Western medicine group and the three YHR groups. HUVECs were stimulated with LPS, then treated separately with the drug-serum containing different concentrations of YHR for 24 h. Then the mRNA expressions of TLR4, MyD88 and TRAF-6 were measured with Real-time PCR, and their protein expressions were analyzed using Western blotting.
RESULTSProtein and mRNA expressions of TLR4, MyD88 and TRAF-6 increased significantly after LPS stimulation (P < 0.01), but the changes in the drug-serum treated groups were significantly lower than those in the saline control group respectively (P < 0.01 or P < 0.05).
CONCLUSIONYHR can block the high expression of TLR4, and also influence the MyD88-dependent signaling pathway of TLR4, suppress the downstream expression of NF-kappaB and various related gene expressions, which may be one of its mechanisms of action for anti-atherosclerosis.
Animals ; Drugs, Chinese Herbal ; pharmacology ; Human Umbilical Vein Endothelial Cells ; drug effects ; metabolism ; Humans ; Male ; Myeloid Differentiation Factor 88 ; metabolism ; Rabbits ; Serum ; TNF Receptor-Associated Factor 6 ; metabolism ; Toll-Like Receptor 4 ; metabolism
5.Effect and mechanism of Bovis Calculus on ulcerative colitis by inhibiting IL-17/IL-17RA/Act1 signaling pathway.
Jian-Mei YUAN ; Dan-Ni LU ; Jia-Jun WANG ; Zhuo XU ; Yong LI ; Mi-Hong REN ; Jin-Xiu LI ; Dao-Yin GONG ; Jian WANG
China Journal of Chinese Materia Medica 2023;48(9):2500-2511
This study aimed to elucidate the effect and underlying mechanism of Bovis Calculus in the treatment of ulcerative colitis(UC) through network pharmacological prediction and animal experimental verification. Databases such as BATMAN-TCM were used to mine the potential targets of Bovis Calculus against UC, and the pathway enrichment analysis was conducted. Seventy healthy C57BL/6J mice were randomly divided into a blank group, a model group, a solvent model(2% polysorbate 80) group, a salazosulfapyridine(SASP, 0.40 g·kg~(-1)) group, and high-, medium-, and low-dose Bovis Calculus Sativus(BCS, 0.20, 0.10, and 0.05 g·kg~(-1)) groups according to the body weight. The UC model was established in mice by drinking 3% dextran sulfate sodium(DSS) solution for 7 days. The mice in the groups with drug intervention received corresponding drugs for 3 days before modeling by gavage, and continued to take drugs for 7 days while modeling(continuous administration for 10 days). During the experiment, the body weight of mice was observed, and the disease activity index(DAI) score was recorded. After 7 days of modeling, the colon length was mea-sured, and the pathological changes in colon tissues were observed by hematoxylin-eosin(HE) staining. The levels of tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β), interleukin-6(IL-6), and interleukin-17(IL-17) in colon tissues of mice were detected by enzyme-linked immunosorbent assay(ELISA). The mRNA expression of IL-17, IL-17RA, Act1, TRAF2, TRAF5, TNF-α, IL-6, IL-1β, CXCL1, CXCL2, and CXCL10 was evaluated by real-time polymerase chain reaction(RT-PCR). The protein expression of IL-17, IL-17RA, Act1, p-p38 MAPK, and p-ERK1/2 was investigated by Western blot. The results of network pharmacological prediction showed that Bovis Calculus might play a therapeutic role through the IL-17 signaling pathway and the TNF signaling pathway. As revealed by the results of animal experiments, on the 10th day of drug administration, compared with the solvent model group, all the BCS groups showed significantly increased body weight, decreased DAI score, increased colon length, improved pathological damage of colon mucosa, and significantly inhibited expression of TNF-α,IL-6,IL-1β, and IL-17 in colon tissues. The high-dose BCS(0.20 g·kg~(-1)) could significantly reduce the mRNA expression levels of IL-17, Act1, TRAF2, TRAF5, TNF-α, IL-6, IL-1β, CXCL1, and CXCL2 in colon tissues of UC model mice, tend to down-regulate mRNA expression levels of IL-17RA and CXCL10, significantly inhibit the protein expression of IL-17RA,Act1,and p-ERK1/2, and tend to decrease the protein expression of IL-17 and p-p38 MAPK. This study, for the first time from the whole-organ-tissue-molecular level, reveals that BCS may reduce the expression of pro-inflammatory cytokines and chemokines by inhibiting the IL-17/IL-17RA/Act1 signaling pathway, thereby improving the inflammatory injury of colon tissues in DSS-induced UC mice and exerting the effect of clearing heat and removing toxins.
Mice
;
Animals
;
Colitis, Ulcerative/metabolism*
;
Tumor Necrosis Factor-alpha/metabolism*
;
Interleukin-6/metabolism*
;
Interleukin-17/pharmacology*
;
TNF Receptor-Associated Factor 2/pharmacology*
;
TNF Receptor-Associated Factor 5/metabolism*
;
Mice, Inbred C57BL
;
Signal Transduction
;
Colon
;
p38 Mitogen-Activated Protein Kinases/metabolism*
;
RNA, Messenger/metabolism*
;
Dextran Sulfate/metabolism*
;
Disease Models, Animal
6.TRAF6 promotes Bacillus Calmette-Guérin-induced macrophage apoptosis through the intrinsic apoptosis pathway.
Qin Mei MA ; Li LIU ; Jia Lin YU ; Zhao Qian GONG ; Xiao Ping WANG ; Xiao Ling WU ; Guang Cun DENG
Journal of Southern Medical University 2022;42(9):1279-1287
OBJECTIVE:
To investigate the role of tumor necrosis factor receptor-associated factor 6 (TRAF6) in regulating Bacillus Calmette-Guérin (BCG)-induced macrophage apoptosis.
METHODS:
The expression of TRAF6 in peripheral blood samples of 50 patients with active tuberculosis (TB) and 50 healthy individuals were detected using quantitative real-time PCR (qPCR). RAW264.7 macrophages were infected with BCG at different MOI and for different lengths of time, and the changes in expressions of Caspase 3 and TRAF6 were detected with Western blotting and qPCR. In a RAW264.7 cell model of BCG infection with TRAF6 knockdown established using RNA interference technique, the bacterial load was measured and cell apoptotic rate and mitochondrial membrane potential (MMP) were determined with flow cytometry. The expression levels of TRAF6, Caspase 3, PARP, BAX and Bcl-2 in the cells were detected using Western blotting, and the expressions of TRAF6 and Caspase 3 were also examined with immunofluorescence assay.
RESULTS:
The expression of TRAF6 was significantly upregulated in the peripheral blood of patients with active TB as compared with healthy subjects (P < 0.001). In RAW264.7 cells, BCG infection significantly increased the expressions of Caspase 3 and TRAF6, which were the highest in cells infected for 18 h and at the MOI of 15. TRAF6 knockdown caused a significant increase of bacterial load in BCG-infected macrophages (P=0.05), lowered the cell apoptotic rate (P < 0.001) and reduced the expressions of Caspase 3 (P=0.002) and PARP (P < 0.001). BCG-infected RAW264.7 cells showed a significantly increased MMP (P < 0.001), which was lowered by TRAF6 knockdown (P < 0.001); the cells with both TRAF6 knockdown and BCG infection showed a lowered BAX expression (P=0.005) and an increased expression of Bcl-2 (P=0.04).
CONCLUSION
TRAF6 promotes BCG-induced macrophage apoptosis by regulating the intrinsic apoptosis pathway.
Apoptosis
;
BCG Vaccine
;
Caspase 3/metabolism*
;
Humans
;
Intracellular Signaling Peptides and Proteins
;
Macrophages
;
Mycobacterium bovis/metabolism*
;
Poly(ADP-ribose) Polymerase Inhibitors
;
TNF Receptor-Associated Factor 6/metabolism*
;
bcl-2-Associated X Protein/metabolism*
7.Construction of TRAF6 ubiquitin site 331 mutant colorectal cancer cell stable line and its effect on biological behavior of colorectal cancer cells.
Ruo Fan HE ; Qin WANG ; Chun Lin LIN ; Peng Hang LIN ; Hui CHEN ; Yong Jian HUANG ; Shu Gang YANG ; Jian Xin YE ; Guang Wei ZHU
Chinese Journal of Oncology 2023;45(2):129-137
Objective: To investigate the effect of ubiquitin mutation at position 331 of tumor necrosis factor receptor related factor 6 (TRAF6) on the biological characteristics of colorectal cancer cells and its mechanism. Methods: lentivirus wild type (pCDH-3×FLAG-TRAF6) and mutation (pCDH-3×FLAG-TRAF6-331mut) of TRAF6 gene expression plasmid with green fluorescent protein tag were used to infect colorectal cancer cells SW480 and HCT116, respectively. The infection was observed by fluorescence microscope, and the expressions of TRAF6 and TRAF6-331mut in cells was detected by western blot. Cell counting kit-8 (CCK-8) and plate cloning test were used to detect the proliferation ability of colorectal cancer cells in TRAF6 group and TRAF6-331mut group, cell scratch test to detect cell migration, Transwell chamber test to detect cell migration and invasion, immunoprecipitation to detect the ubiquitination of TRAF6 and TRAF6-331mut with ubiquitinof lysine binding sites K48 and K63. Western blot was used to detect the effects of TRAF6 and TRAF6-331mut over expression on the nuclear factor kappa-B (NF-κB) and mitogen activated protein kinase mitogen-activated protein kinase (MAPK)/activating protein-1(AP-1) signal pathway. Results: The successful infection of colorectal cancer cells was observed under fluorescence microscope. Western blot detection showed that TRAF6 and TRAF6-331mut were successfully expressed in colorectal cancer cells. The results of CCK-8 assay showed that on the fourth day, the absorbance values of HCT116 and SW480 cells in TRAF6-331mut group were 1.89±0.39 and 1.88±0.24 respectively, which were lower than those in TRAF6 group (2.09±0.12 and 2.17±0.45, P=0.036 and P=0.011, respectively). The results of plate colony formation assay showed that the number of clones of HCT116 and SW480 cells in TRAF6-331mut group was 120±14 and 85±14 respectively, which was lower than those in TRAF6 group (190±21 and 125±13, P=0.001 and P=0.002, respectively). The results of cell scratch test showed that after 48 hours, the percentage of wound healing distance of HCT116 and SW480 cells in TRAF6-331mut group was (31±12)% and (33±14)%, respectively, which was lower than those in TRAF6 group [(43±13)% and (43±7)%, P=0.005 and 0.009, respectively]. The results of Transwell migration assay showed that the migration numbers of HCT116 and SW480 cells in TRAF6-331mut group were significantly lower than those in TRAF6 group (P<0.001 and P<0.002, respectively). The results of Transwell invasion assay showed that the number of membrane penetration of HCT116 and SW480 cells in TRAF6-331mut group was significantly lower than those in TRAF6 group (P=0.008 and P=0.009, respectively). The results of immunoprecipitation detection showed that the ubiquitin protein of K48 chain pulled by TRAF6-331mut was lower than that of wild type TRAF6 in 293T cells co-transfected with K48 (0.57±0.19), and the ubiquitin protein of K63 chain pulled down by TRAF6-331mut in 293T cells co-transfected with K63 was lower than that of wild type TRAF6 (0.89±0.08, P<0.001). Western blot assay showed that the protein expression levels of NF-κB, p-NF-κB and p-AP-1 in TRAF6-331mut-HCT116 cells were 0.63±0.08, 0.42±0.08 and 0.60±0.07 respectively, which were lower than those in TRAF6-HCT116 cells (P=0.002, P<0.001 and P<0.001, respectively). The expression level of AP-1 protein in TRAF6-HCT116 cells was 0.89±0.06, compared with that in TRAF6-HCT116 cells. The difference was not statistically significant (P>0.05). The protein expression levels of NF-κB, p-NF-κB and p-AP-1 in TRAF6-331mut-SW480 cells were 0.50±0.06, 0.51±0.04, 0.48±0.02, respectively, which were lower than those in TRAF6-SW480 cells (all P<0.001). There was no significant difference in AP-1 protein expression between TRAF6-331mut-SW480 cells and TRAF6-SW480 cells. Conclusion: The ubiquitin site mutation of TRAF6 gene at 331 may prevent the binding of TRAF6 and ubiquitin lysine sites K48 and K63, and then affect the expressions of proteins related to downstream NF-κB and MAPK/AP-1 signal pathways, and inhibit the proliferation, migration and invasion of colorectal cancer cells.
Humans
;
Cell Line, Tumor
;
Cell Movement
;
Cell Proliferation
;
Colorectal Neoplasms/pathology*
;
Lysine/metabolism*
;
NF-kappa B/metabolism*
;
TNF Receptor-Associated Factor 6/metabolism*
;
Transcription Factor AP-1/metabolism*
;
Ubiquitin/metabolism*
8.Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6.
Fan-Cong KONG ; Jing-Qiong ZHANG ; Chen ZENG ; Wen-Lan CHEN ; Wen-Xiang REN ; Guo-Xin YAN ; Hong-Xiang WANG ; Qiu-Bai LI ; Zhi-Chao CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2015;35(3):343-349
This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-κB in multiple myeloma (MM). Human multiple myeloma cell line RPMI 8226 cells were treated with or without different concentrations of PTL for various time periods, and then MTT assay was used to detect cell proliferation. Cell cycle and apoptosis were flow cytometrically detected. The level of protein ubiquitination was determined by using immunoprecipitation. Western blotting was employed to measure the level of total protein ubiquitination, the expression of IκB-α in cell plasma and the content of p65 in nucleus. The content of p65 in nucleus before and after PTL treatment was also examined with immunofluorescence. Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IκB-α and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-κB. PTL inhibited cell proliferation, induced apoptosis and blocked cell cycle. Furthermore, the levels of ubiquitinated tumor necrosis factor receptor-associated factor 6 (TRAF6) and total proteins were decreased after PTL treatment. By using Autodock software package, we predicted that PTL could bind to TRAF6 directly and tightly. Taken together, our findings suggest that PTL inhibits the activation of NF-κB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis.
Apoptosis
;
Cell Cycle
;
drug effects
;
Cell Line, Tumor
;
Cell Proliferation
;
drug effects
;
Humans
;
Multiple Myeloma
;
drug therapy
;
metabolism
;
NF-kappa B
;
antagonists & inhibitors
;
blood
;
Sesquiterpenes
;
pharmacology
;
TNF Receptor-Associated Factor 6
;
metabolism
;
Transcription Factor RelA
;
metabolism
;
Ubiquitination
;
drug effects
9.Regulatory effects of AT₁R-TRAF6-MAPKs signaling on proliferation of intermittent hypoxia-induced human umbilical vein endothelial cells.
Jin SHANG ; Xue-Ling GUO ; Yan DENG ; Xiao YUAN ; Hui-Guo LIU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2015;35(4):495-501
Endothelial dysfunction induced by intermittent hypoxia (IH) participates in obstructive sleep apnea syndrome (OSAS)-associated cardiovascular disorders. Myeloid differentiation primary response 88 (MyD88) and tumor necrosis factor receptor-associated factor 6 (TRAF6) regulate numerous downstream adaptors like mitogen-activated protein kinases (MAPKs) and the subsequent oxidative stress and inflammatory responses. This study aimed to characterize the role of MyD88/TRAF6 in IH-treated cell function and its associated signaling. Human umbilical vein endothelial cells (HUVECs) were randomly exposed to IH or normoxia for 0, 2, 4 and 6 h. Western blotting was used to detect the expression pattern of target gene proteins [angiotensin 1 receptor (AT1R), p-ERK1/2, p-p38MAPK, MyD88 and TRAF6], and the relationships among these target genes down-regulated by the corresponding inhibitors were studied. Finally, the influence of these target genes on proliferation of HUVECs was also assessed by EdU analysis. Protein levels of AT1R, TRAF6 and p-ERK1/2 were increased after IH exposure, with a slight rise in MyD88 and a dynamic change in p-p38MAPK. The down-regulation of TRAF6 by siRNA reduced ERK1/2 phosphorylation during IH without any effects on AT1R. Blockade of AT1R with valsartan decreased TRAF6 and p-ERK1/2 protein expression after IH exposure. ERK1/2 inhibition with PD98059 suppressed only AT1R expression. IH promoted HUVECs proliferation, which was significantly suppressed by the inhibition of TRAF6, AT1R and ERK1/2. The findings demonstrate that TRAF6 regulates the proliferation of HUVECs exposed to short-term IH by modulating cell signaling involving ERK1/2 downstream of AT1R. Targeting the AT1R-TRAF6-p-ERK1/2 signaling pathway might be helpful in restoring endothelial function.
Cell Hypoxia
;
Cell Proliferation
;
Cells, Cultured
;
Gene Expression Regulation
;
Human Umbilical Vein Endothelial Cells
;
physiology
;
Humans
;
MAP Kinase Signaling System
;
drug effects
;
Phosphorylation
;
Receptor, Angiotensin, Type 1
;
genetics
;
metabolism
;
TNF Receptor-Associated Factor 6
;
genetics
;
metabolism
;
Valsartan
;
pharmacology
10.Effect of Dureping injection on TIR signal pathway on Ana-1 cells.
Yanli ZHANG ; Ningping WANG ; Ligang GU ; Pengtao LI
China Journal of Chinese Materia Medica 2010;35(6):741-744
OBJECTIVETo investigate the influence of Dureping injection to the murinal celiac macrophage Ana-1 on TIR signal pathway.
METHODAna-1 cell line was infected by influenza virus FM1 strain and treated with the Dureping injection in different concentrations (10.1 mg x L(-1) group) for 12 h and 24 h. Then we collected the cells, extracted mRNA and measured the expressions of TLR7, MyD88, IRAK4, TRAF6 and NF-kappaB p65 respectively by RT-PCR.
RESULTDureping injection down-regulated the expression of TLR7, MyD88, IRAK4, TRAF6 and NF-kappaB p65 mRNA in Ana-1 cell line infected by influenza virus, in a dose-dependent manner significantly.
CONCLUSIONDureping injection has an obvious effect against influenza virus FM1 strain by regulating the TIR signal pathway.
Adaptor Proteins, Signal Transducing ; Animals ; Cells ; Cells, Cultured ; Epithelial Cells ; drug effects ; metabolism ; Interleukin-1 Receptor-Associated Kinases ; genetics ; Macrophages ; drug effects ; metabolism ; Mice ; Myeloid Differentiation Factor 88 ; genetics ; metabolism ; NF-kappa B ; metabolism ; RNA, Messenger ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Signal Transduction ; drug effects ; TNF Receptor-Associated Factor 6 ; drug effects ; genetics ; metabolism ; Transcription Factor RelA ; metabolism